NSE · Healthcare · Drug Manufacturers - Specialty & Generic
with an average price target of ₹1,020.00.
| Document | Date |
|---|---|
| Annual report FY2026 SAKAR HEALTHCARE LIMITED – ANNUAL REPORT FY 2025-26 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Revenue from operations: Rs. 25,173.60 lakhs (FY | 2026-08-27 |
| Q1 FY27 earnings call SAKAR HEALTHCARE LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Revenue from operations Q1 FY27: INR 7,297 lakhs (INR 72.97 crores), up 38% y | 2026-08-03 |
| Investor presentation SAKAR HEALTHCARE LIMITED – Q1 FY27 INVESTOR SUMMARY --- HEADLINE NUMBERS • Revenue from Operations Q1 FY27: ₹7,297 lakhs, up 38% YoY (Q1 FY26: ₹5,2 | 2026-07-28 |
| Quarterly results · Q1 FY27 SAKAR HEALTHCARE LIMITED – Q1FY27 FINANCIAL SUMMARY HEADLINE NUMBERS • Revenue from Operations: ₹7,297.25 lakhs in Q1FY27, up 38% year-on-year from | 2026-07-24 |
| Quarterly results · Q4 FY26 SAKAR HEALTHCARE LIMITED – FINANCIAL RESULTS SUMMARY Year Ended 31 March 2026 --- HEADLINE NUMBERS • Revenue from Operations (FY2026): Rs 25,173.60 | 2026-06-13 |
| Q4 FY26 earnings call SAKAR HEALTHCARE LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: INR 7,109.70 lakhs vs INR 5,024.18 lakhs in Q4 FY25 – 42% ye | 2026-05-22 |
| Investor presentation · Q4 FY26 SAKAR HEALTHCARE LIMITED – Q4FY26 INVESTOR SUMMARY HEADLINE NUMBERS • Revenue FY26: ₹25,174 lakhs (42% YoY growth from ₹17,758 lakhs FY25) • Q4FY26 | 2026-05-13 |
| Quarterly results | 2026-02-19 |
Readable in the app.
| Announcement | Date |
|---|---|
| Award for remarkable performance and excellence in contractual commitments Sakar Healthcare Limited has received an award from Ethiopian Pharmaceutical Supply Services (EPSS) recognizing the company's excellent performance and strong adherence to contractual obliga | 2026-04-30 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Sakar Healthcare Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.